• Ovarian Cancer Risk in Fertility Assistance Rises Mainly for Women with Endometriosis, Study Suggests
  • Opdivo-Avastin Combo Safe, Has Strong Activity in Relapsed Ovarian Cancer Patients, Phase 2 Trial Shows
  • CA125 Blood Test May Help Alert GPs to Ovarian and Other Cancers, Research Shows
  • Syros’ SY-5609 Shows Promising Activity in OC Models, Supports Planned Phase 1 Trial, Results Show
  • OTL38 ‘Lights up’ Ovarian Cancer Cells, Helping Surgeons to Remove Them, Phase 2 Study Shows
  • Zejula Maintenance Increases Time Without Symptoms or Toxicity in Recurrent OC Patients, Study Says
  • Lynparza-Avastin First-Line Maintenance Therapy Delays Cancer Progression in Advanced OC, Phase 3 Study Shows
  • Trabectedin, Bevacizumab, Platinum Chemotherapy Combo May Work, But Safety a Concern, Study Finds
  • FDA Approves Zejula as Late-Line Treatment for Recurrent Ovarian Cancer Patients
  • New Microscope Technique Improves Metastasis Detection in Ovarian Cancer Patients
  • Ovarian Cancer Research Led By David Alberts Given Boost By $5M Memorial Gift
  • NICE Favors Adding Rubraca to NHS England to Treat Relapsed Ovarian Cancer